MODEL VERDICT
Cytek Biosciences, Inc. (CTKB)
Relative Valuation•Peer multiples, Monte Carlo simulation & quality-adjusted fair value
Popular:
Composite score derived from valuation, quality, and risk factors
Quantitative model thresholds · For educational and research purposes only
Each row records the model's monthly assessment. High Conviction = the model detected notable undervaluation vs peers. Neutral = no notable divergence was found. The return column shows the actual price change over 90 days for reference. This is a quantitative observation log — not investment advice.
| Date | Assessment | Score | Price | Status | 90d Fwd Return |
|---|---|---|---|---|---|
| May 8, 2026 | MODERATE | 0.61 | $4.61 | CURRENT | — |
| May 1, 2026 | MODERATE | 0.61 | $4.62 | CURRENT | — |
| Apr 24, 2026 | MODERATE | 0.61 | $4.40 | CURRENT | — |
| Apr 17, 2026 | MODERATE | 0.61 | $4.61 | CURRENT | — |
| Apr 16, 2026 | MODERATE | 0.61 | $4.69 | CURRENT | — |
Historical model observations for research purposes only. Past quantitative patterns do not predict future results. Not a recommendation to buy, sell, or hold any security.
| Methodology | Fair Value | vs Current | Weight | Quality | Status |
|---|---|---|---|---|---|
| EV To Revenue 9 industry peers | $7.46 | +61.8% | 4% | B | Data |
| Price / Sales 9 industry peers | $6.42 | +39.3% | 3% | B | Model Driven |
| Weighted Output Blended model output | $8.57 | +85.9% | 100% | 54 | SIGNIFICANTLY UNDERVALUED |
Cross-sectional regression predicting expected multiples based on growth, margins, ROIC, and beta.
| Multiple | Avg | Median | Min | Max | Std |
|---|---|---|---|---|---|
| P/FCF | 3654.12 | 2717.58 | 38.79 | 8205.99 | 4163.37 |
| P/FFO | 291.96 | 189.63 | 171.79 | 514.45 | 192.89 |
| P/TBV | 3.39 | 3.44 | 2.09 | 5.59 | 1.38 |
| P/B Ratio | 3.18 | 3.14 | 1.89 | 5.38 | 1.38 |
| P/S Ratio | 7.90 | 6.39 | 3.20 | 17.06 | 5.53 |
Based on our peer multiples analysis with 5 valuation metrics, the model estimates CTKB's fair value at $8.57 vs the current price of $4.61, implying +85.9% upside potential. Model verdict: Significantly Undervalued. Confidence: 54/100. This is a quantitative estimate, not a recommendation.
The blended fair value of $8.57 is calculated using four lenses: industry median multiples (40%), historical multiples (30%), forward estimates (20%), and quality-adjusted multiples (10%). Monte Carlo simulation (10,000 iterations) gives a range of $5.79 (P10) to $10.65 (P90), with a median of $8.14.
CTKB's current P/E of -8.9x compares to the industry median of 25.9x (6 peers in the group). This represents a -134.2% discount to the industry. The historical average P/E is N/Ax over 0 years. Signal: Deep Discount.
5 analysts cover CTKB with a consensus rating of Buy. The consensus price target is $6.00 (range: $6.00 — $6.00), implying +30.2% upside from the current price. Grade breakdown: Strong Buy (0), Buy (3), Hold (1), Sell (1), Strong Sell (0).
The model confidence score is 54/100, based on: data completeness (6), peer quality (25), historical depth (16), earnings stability (5), and model agreement (2). Cyclicality penalty: -0 points. The model shows moderate agreement across inputs.
The model flags several key risks: (1) Macro/regulatory risks are not captured in this model but remain material.
Peak earnings risk data is not available for CTKB.
No. This dashboard is a quantitative research tool for educational and informational purposes only. It is not investment advice, a solicitation, or a recommendation to buy, sell, or hold any security. The operator of this platform is not a registered investment advisor (RIA), broker-dealer, or financial planner. All model outputs, fair value estimates, signals, and scenarios are the result of automated quantitative computations and should not be construed as professional financial guidance. You should consult a qualified, licensed financial advisor before making any investment decisions. Past model performance is not indicative of future results.